Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia

Standard

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia : results of a meta-analysis. / Eichhorst, Barbara F; Fischer, Kirsten; Fink, Anna-Maria; Elter, Thomas; Wendtner, Clemens M; Goede, Valentin; Bergmann, Manuela; Stilgenbauer, Stephan; Hopfinger, Georg; Ritgen, Matthias; Bahlo, Jasmin; Busch, Raymonde; Hallek, Michael; German CLL Study Group (GCLLSG) ; Bokemeyer, Carsten.

in: BLOOD, Jahrgang 117, Nr. 6, 10.02.2011, S. 1817-21.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Eichhorst, BF, Fischer, K, Fink, A-M, Elter, T, Wendtner, CM, Goede, V, Bergmann, M, Stilgenbauer, S, Hopfinger, G, Ritgen, M, Bahlo, J, Busch, R, Hallek, M, German CLL Study Group (GCLLSG) & Bokemeyer, C 2011, 'Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis', BLOOD, Jg. 117, Nr. 6, S. 1817-21. https://doi.org/10.1182/blood-2010-04-282228

APA

Eichhorst, B. F., Fischer, K., Fink, A-M., Elter, T., Wendtner, C. M., Goede, V., Bergmann, M., Stilgenbauer, S., Hopfinger, G., Ritgen, M., Bahlo, J., Busch, R., Hallek, M., German CLL Study Group (GCLLSG), & Bokemeyer, C. (2011). Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. BLOOD, 117(6), 1817-21. https://doi.org/10.1182/blood-2010-04-282228

Vancouver

Bibtex

@article{83e153e8f3dd484b953956cc3195e892,
title = "Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis",
abstract = "The clinical value of imaging is well established for the follow-up of many lymphoid malignancies but not for chronic lymphocytic leukemia (CLL). A meta-analysis was performed with the dataset of 3 German CLL Study Group phase 3 trials (CLL4, CLL5, and CLL8) that included 1372 patients receiving first-line therapy for CLL. Response as well as progression during follow-up was reassessed according to the National Cancer Institute Working Group1996 criteria. A total of 481 events were counted as progressive disease during treatment or follow-up. Of these, 372 progressions (77%) were detected by clinical symptoms or blood counts. Computed tomography (CT) scans or ultrasound were relevant in 44 and 29 cases (9% and 6%), respectively. The decision for relapse treatment was determined by CT scan or ultrasound results in only 2 of 176 patients (1%). CT scan results had an impact on the prognosis of patients in complete remission only after the administration of conventional chemotherapy but not after chemoimmunotherapy. In conclusion, physical examination and blood count remain the methods of choice for staging and clinical follow-up of patients with CLL as recommended by the International Workshop on Chronic Lymphocytic Leukemia 2008 guidelines. These trials are registered at http://www.isrctn.org as ISRCTN 75653261 and ISRCTN 36294212 and at http://www.clinicaltrials.gov as NCT00281918.",
keywords = "Antineoplastic Combined Chemotherapy Protocols, Blood Cell Count, Disease Progression, Disease-Free Survival, Female, Follow-Up Studies, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Prognosis, Recurrence, Remission Induction, Tomography, X-Ray Computed",
author = "Eichhorst, {Barbara F} and Kirsten Fischer and Anna-Maria Fink and Thomas Elter and Wendtner, {Clemens M} and Valentin Goede and Manuela Bergmann and Stephan Stilgenbauer and Georg Hopfinger and Matthias Ritgen and Jasmin Bahlo and Raymonde Busch and Michael Hallek and {German CLL Study Group (GCLLSG)} and Carsten Bokemeyer",
year = "2011",
month = feb,
day = "10",
doi = "10.1182/blood-2010-04-282228",
language = "English",
volume = "117",
pages = "1817--21",
journal = "BLOOD",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

RIS

TY - JOUR

T1 - Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia

T2 - results of a meta-analysis

AU - Eichhorst, Barbara F

AU - Fischer, Kirsten

AU - Fink, Anna-Maria

AU - Elter, Thomas

AU - Wendtner, Clemens M

AU - Goede, Valentin

AU - Bergmann, Manuela

AU - Stilgenbauer, Stephan

AU - Hopfinger, Georg

AU - Ritgen, Matthias

AU - Bahlo, Jasmin

AU - Busch, Raymonde

AU - Hallek, Michael

AU - German CLL Study Group (GCLLSG)

AU - Bokemeyer, Carsten

PY - 2011/2/10

Y1 - 2011/2/10

N2 - The clinical value of imaging is well established for the follow-up of many lymphoid malignancies but not for chronic lymphocytic leukemia (CLL). A meta-analysis was performed with the dataset of 3 German CLL Study Group phase 3 trials (CLL4, CLL5, and CLL8) that included 1372 patients receiving first-line therapy for CLL. Response as well as progression during follow-up was reassessed according to the National Cancer Institute Working Group1996 criteria. A total of 481 events were counted as progressive disease during treatment or follow-up. Of these, 372 progressions (77%) were detected by clinical symptoms or blood counts. Computed tomography (CT) scans or ultrasound were relevant in 44 and 29 cases (9% and 6%), respectively. The decision for relapse treatment was determined by CT scan or ultrasound results in only 2 of 176 patients (1%). CT scan results had an impact on the prognosis of patients in complete remission only after the administration of conventional chemotherapy but not after chemoimmunotherapy. In conclusion, physical examination and blood count remain the methods of choice for staging and clinical follow-up of patients with CLL as recommended by the International Workshop on Chronic Lymphocytic Leukemia 2008 guidelines. These trials are registered at http://www.isrctn.org as ISRCTN 75653261 and ISRCTN 36294212 and at http://www.clinicaltrials.gov as NCT00281918.

AB - The clinical value of imaging is well established for the follow-up of many lymphoid malignancies but not for chronic lymphocytic leukemia (CLL). A meta-analysis was performed with the dataset of 3 German CLL Study Group phase 3 trials (CLL4, CLL5, and CLL8) that included 1372 patients receiving first-line therapy for CLL. Response as well as progression during follow-up was reassessed according to the National Cancer Institute Working Group1996 criteria. A total of 481 events were counted as progressive disease during treatment or follow-up. Of these, 372 progressions (77%) were detected by clinical symptoms or blood counts. Computed tomography (CT) scans or ultrasound were relevant in 44 and 29 cases (9% and 6%), respectively. The decision for relapse treatment was determined by CT scan or ultrasound results in only 2 of 176 patients (1%). CT scan results had an impact on the prognosis of patients in complete remission only after the administration of conventional chemotherapy but not after chemoimmunotherapy. In conclusion, physical examination and blood count remain the methods of choice for staging and clinical follow-up of patients with CLL as recommended by the International Workshop on Chronic Lymphocytic Leukemia 2008 guidelines. These trials are registered at http://www.isrctn.org as ISRCTN 75653261 and ISRCTN 36294212 and at http://www.clinicaltrials.gov as NCT00281918.

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Blood Cell Count

KW - Disease Progression

KW - Disease-Free Survival

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Leukemia, Lymphocytic, Chronic, B-Cell

KW - Male

KW - Middle Aged

KW - Prognosis

KW - Recurrence

KW - Remission Induction

KW - Tomography, X-Ray Computed

U2 - 10.1182/blood-2010-04-282228

DO - 10.1182/blood-2010-04-282228

M3 - SCORING: Journal article

C2 - 21139079

VL - 117

SP - 1817

EP - 1821

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 6

ER -